Effects of saikosaponin-d on CYP3A4 in HepaRG cell and protein-ligand docking study
© 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)..
Saikosaponin-d (SSd) is a major bioactive triterpenoid saponin extracted from Bupleurum, which has anti-inflammatory, anticancer, antioxidative and anti-hepatic fibrosis effects. Due to the effects of Bupleurum-related formulations on cytochrome P450 (CYPs) expression still remain unclear, the combination therapies involved formulations containing Bupleurum may sometimes lead to unexpected drug-drug interactions in clinical practice. These interactions can limit the clinical applications of related formulations. In this study, we tried to explore the effects of SSd on CYP3A4 mRNA, protein expression and the enzyme activity in HepaRG cells by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR), Western blot (WB) and HPLC method, respectively. The interaction between SSd and CYP3A4 was analysed by molecular docking. HepaRG cells were cultured with different concentrations of SSd (0.5, 1, 5 and 10 μmol/L) for 72 hours. It is revealed that SSd can inhibit CYP3A4 mRNA and its protein expression, and also the enzyme activity. Molecular docking study demonstrated that SSd can bind to several key active sites of amino acid residues of CYP3A4 protein with hydrogen bonds and hydrophobic interactions. Thus, drug-drug interactions resulted by SSd inhibiting CYP3A4 need attention when formulations containing SSd or Bupleurum are co-administrated with drugs metabolized by CYP3A4.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
Basic & clinical pharmacology & toxicology - 128(2021), 5 vom: 05. Mai, Seite 661-668 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Hongfang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.11.2021 Date Revised 08.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcpt.13552 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319333825 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319333825 | ||
| 003 | DE-627 | ||
| 005 | 20231225171228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcpt.13552 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319333825 | ||
| 035 | |a (NLM)33369126 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Hongfang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of saikosaponin-d on CYP3A4 in HepaRG cell and protein-ligand docking study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2021 | ||
| 500 | |a Date Revised 08.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). | ||
| 520 | |a Saikosaponin-d (SSd) is a major bioactive triterpenoid saponin extracted from Bupleurum, which has anti-inflammatory, anticancer, antioxidative and anti-hepatic fibrosis effects. Due to the effects of Bupleurum-related formulations on cytochrome P450 (CYPs) expression still remain unclear, the combination therapies involved formulations containing Bupleurum may sometimes lead to unexpected drug-drug interactions in clinical practice. These interactions can limit the clinical applications of related formulations. In this study, we tried to explore the effects of SSd on CYP3A4 mRNA, protein expression and the enzyme activity in HepaRG cells by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR), Western blot (WB) and HPLC method, respectively. The interaction between SSd and CYP3A4 was analysed by molecular docking. HepaRG cells were cultured with different concentrations of SSd (0.5, 1, 5 and 10 μmol/L) for 72 hours. It is revealed that SSd can inhibit CYP3A4 mRNA and its protein expression, and also the enzyme activity. Molecular docking study demonstrated that SSd can bind to several key active sites of amino acid residues of CYP3A4 protein with hydrogen bonds and hydrophobic interactions. Thus, drug-drug interactions resulted by SSd inhibiting CYP3A4 need attention when formulations containing SSd or Bupleurum are co-administrated with drugs metabolized by CYP3A4 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CYP3A4 | |
| 650 | 4 | |a HepaRG cell | |
| 650 | 4 | |a drug-drug interaction | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a saikosaponin-d | |
| 650 | 7 | |a Cytochrome P-450 CYP3A Inhibitors |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Saponins |2 NLM | |
| 650 | 7 | |a Oleanolic Acid |2 NLM | |
| 650 | 7 | |a 6SMK8R7TGJ |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a CYP3A4 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.55 |2 NLM | |
| 650 | 7 | |a saikosaponin D |2 NLM | |
| 650 | 7 | |a UR635J3F00 |2 NLM | |
| 700 | 1 | |a Tang, Yunyan |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Weipeng |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Chengchen |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Fushan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Basic & clinical pharmacology & toxicology |d 2004 |g 128(2021), 5 vom: 05. Mai, Seite 661-668 |w (DE-627)NLM144330768 |x 1742-7843 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2021 |g number:5 |g day:05 |g month:05 |g pages:661-668 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcpt.13552 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2021 |e 5 |b 05 |c 05 |h 661-668 | ||